Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

NCT06789913 is registered in ClinicalTrials.gov with Relay Therapeutics, Inc. as lead sponsor.

NCT NCT06789913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06789913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Lead sponsor
Relay Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 13, 2025
Completion date
October 31, 2031
Enrollment
277 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

cloves syndrome, klippel trenaunay syndrome, lymphatic malformations, megalencephaly-capillary malformation polymicrogyria syndrome (mcap), pik3ca mutation, pik3ca-related overgrowth spectrum (pros), vascular anomalies, vascular malformations